45 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22759 | EGFR mutation : Ex19del, L858R, alone or in combination with T790M mutation. | Thierry Berghmans | NSCLC | AstraZeneca | D5164C00001 ADAURA | Trial closed for recruitment | A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) | 3 | 3 | ||
| 29685 | Mariana Brandao | Lung | Sanofi-Aventis | EFC15858/CARMEN-LC03 | Trial closed for recruitment | Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors | mariana.brandao@hubruxelles.be | 3 | 3 | ||
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 22688 | At least one prior platinum-based systemic regimen/ RET | Thierry Berghmans | NSCLC | IBCSG | ETOP 12-17 ALERT-lung | Trial closed | A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC (ETOP 12-17 ALERT-lung) | 2 | 2 | ||
| 28490 | Thierry Berghmans | Lung | Roche | GO41892 - (CONTACT-01) | Trial closed for recruitment | A phase III, multicenter, randomized, open-label, controlled study to evaluate the efficacy, safety, and pharmacokinetics of tezolizumab given in combination with cabozantinib versus docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy | 3 | 3 | |||
| 22754 | Brain metastasis | Ahmad Hussein Awada | Multiple | Lilly | I3Y-MC-JPBO | Trial closed | A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer, non-small cell lung cancer, or melanoma | ahmad.awada@hubruxelles.be | 2 | 2 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22650 | vaccine, diarrhea, clostridium | Multiple | Pfizer | IJB_2672 | Trial closed | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 3 | 3 | |||
| 22628 | Reduced left ventricular ejection fraction | Thierry Berghmans | Lung | Institut Jules Bordet | IJB_2707 | Trial closed | Cardiovascular morbidities and lung cancer treatment : a prospective registry | ||||
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
| 22657 | Metastatic, Biopsy mandatory | Nuria Kotecki | Multiple | Lilly | IJB_2732 | Trial closed | A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors | Nuria.Kotecki@hubruxelles.be | 1/1b | 1 | |
| 28521 | NSCLC | Thierry Berghmans | Lung | Amgen | IJB_3116 | Trial closed for recruitment | A Phase 3 Multicenter, Randomized, Open-label, Active-controlled, Study of AMG 510 versus Docetaxel for the treatment of Previously treated locally Advanced and unresectable or Metastatic NSCLC Subjects with mutated KRAS p.G12C | 3 | 3 | ||
| 22662 | second line, RECIST 1.1, Biopsy | Philippe Aftimos | Multiple | Incyte Corporate | INCAGN1876-201 | Trial closed | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22640 | Metastatic, Biopsy mandatory | Christiane Jungels | Multiple | Incyte Corporate | INCB 01158-203 | Trial closed | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. (INCB01158-203) | christiane.jungels@hubruxelles.be | 1 | 1 |